Steep valuations and uncertainty about adoption have created a lot of volatility in the shares of HeartWare International (NASDAQ: HTWR ) and Thoratec (NASDAQ: THOR )
, the leading developers of ventricular assist devices or VADs that
help seriously ill heart failure patients live longer, better lives.
While these companies serve a patient population that is desperately in
need of better therapy and can support over $1 billion in revenue, there
has always been a bigger market in less seriously ill heart failure
patients. Sunshine Heart (NASDAQ: SSH )
has advanced a very interesting approach for these patients into a
pivotal U.S. study, while HeartWare has just recently acquired its own
pathway into what could be a multibillion dollar opportunity.
Continue here to The Motley Fool:
New Ideas Offer Hope for Both Heart Failure Patients and Investors
No comments:
Post a Comment